Implementation of a Return Home With a Hospitalization at Home or With a Home Health Care Provider From the Services of Oncopneumology, Oncology and Hematology of University Hospital of Strasbourg

Implementation of a Return Home With a Hospitalization at Home or With a Home Health Care Provider From the Services of Oncopneumology, Oncology and Hematology of University Hospital of Strasbourg: Observational, Prospective, Monocentric, Non-interventional Study. Advantages, Disadvantages, Limitations

Hospitalization at home is booming. It is designed to meet the demands of patients and their families to continue care at home. It partially solves the problem of the lack of places in the "long-term care" structures and allows to respond to a desire of the health policy to reduce the lengths of stay in the hospital. Hospitalization at home is also an alternative in the management of chronic patients. Nevertheless, at the moment a certain number of requests for hospitalization at home remain unsuccessful or their implementation is complicated. In addition, the number of home health care provider has increased significantly in recent years. According to the federation of home health care provider, the number of beneficiaries increased by 1.7% in 4 years. The home health care provider would support 1,200,000 patients per year.

The objective of the study is to analyze the factors participating in Implementation of a return home with a Hospitalization at home or a home health care provider during a return home project constructed with the patient and his / her relatives from the services of Oncology, oncology, hematology of the University Hospital of Strasbourg.

Study Overview

• Status: Unknown
• Conditions: Cancer

• Study Type: Observational
• Enrollment (Anticipated): 100

Contacts and Locations

Study Locations

• France
  • Strasbourg, France, 67098
    • Recruiting
    • Service Soins Palliatifs
    • Principal Investigator: Laurent Calvel, MD, PhD
    • Contact: Marie DEMEUSE, MD; Phone Number: 33 3 88 12 83 39; Email: marie.demeuse@chru-strasbourg.fr
    • Contact: Laurent CALVEL; Phone Number: 33 3 88 12 83 39; Email: laurent.calvel@chru-strasbourg.fr
    • Sub-Investigator: Marie DEMEUSE, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patient over 18 years old for whom an application for Hospitalization at home or with a home health provider is initiated by the Oncology, Oncology or Hematology Department of of the University Hospital of Strasbourg.

Description

Inclusion Criteria:

• Patient over 18 years old
• Patient for whom an application for Hospitalization at home or with a home health provider is initiated by the Oncology, Oncology or Hematology Department of the University Hospital of Strasbourg.

Exclusion Criteria:

• Refusal to participate in the study

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Analysis of factors participating in Implementation of a return home with a Hospitalization at home or a home health care provider	15 days after patient discharge from hospital

Collaborators and Investigators

• Sponsor: University Hospital, Strasbourg, France
• Investigators: Study Director: Laurent CALVEL, MD, PhD, University Hospital, Strasbourg, France; Principal Investigator: Marie DEMEUSE, MD, University Hospital, Strasbourg, France

Study record dates

Study Major Dates

• Study Start (Actual): July 12, 2017
• Primary Completion (Anticipated): July 1, 2018
• Study Completion (Anticipated): July 1, 2018

Study Registration Dates

• First Submitted: July 11, 2017
• First Submitted That Met QC Criteria: July 13, 2017
• First Posted (Actual): July 14, 2017

Study Record Updates

• Last Update Posted (Actual): July 14, 2017
• Last Update Submitted That Met QC Criteria: July 13, 2017
• Last Verified: July 1, 2017

More Information

Terms related to this study

• Keywords: palliative care; Cancer; hospitalization at home; home health care provider
• Other Study ID Numbers: 6843

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No